$NBIX Neurocrine Biosciences (NBIX) Overall Average: 72% Buy.

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
$NBIX Overall Average: 72% Buy. $WDC $GT $BRCM

Neurocrine Biosciences (NBIX) Buy - Hold - Sell - Overall Opinion

NBIX Last Price: 18.08
Current Change: -0.43 (-2.32%)

Composite Indicators - Signal
TrendSpotter- Buy

Short Term Indicators
7 Day Average Directional Indicator- Buy
10 - 8 Day Moving Average Hilo Channel- Buy
20 Day Moving Average vs Price- Buy
20 - 50 Day MACD Oscillator- Buy
20 Day Bollinger Bands- Buy

Short Term Indicators Average: 100% Buy
20-Day Average Volume - 1,722,345


Medium Term Indicators
40 Day Commodity Channel Index- Buy
50 Day Moving Average vs Price- Buy
20 - 100 Day MACD Oscillator - Sell
50 Day Parabolic Time/Price- Buy

Medium Term Indicators Average: 50% Buy
50-Day Average Volume - 1,044,092

Long Term Indicators
60 Day Commodity Channel Index- Buy
100 Day Moving Average vs Price- Buy
50 - 100 Day MACD Oscillator - Sell

Long Term Indicators Average: 33% Buy
100-Day Average Volume - 1,105,391

Overall Average: 72% Buy

Price - Support - Pivot Point - Resistance
18.08 16.73 17.79 18.85


Last Updated: Thursday, January 9, 2014 08:43:11 AM

NBIX Stock Message Board and Forum http://investorshangout.com/search?q=NBIX&...mp;yt0=Go!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Navigating Early Career Challenges: Strategies for Success

Updated Category News Views 159

Understanding the Challenges of Early Career Professionals As the new generation of professionals prepares to step into the workforce, they often face a variety of challenges. Recent insights from professionals reveal common hurdles that individuals might encounter early in their careers. Understanding these challenges is the first step toward successfully navigating...

Continue Reading
Pharming Takes Strategic Step with Public Offer for Abliva AB

Updated Category News Views 387

Pharming Sets a New Course with Strategic Acquisition Strengthening the Pipeline with a First-in-Disease Asset Pharming Group N.V. has recently made headlines with its ambitious public cash offer for Abliva AB. This strategic acquisition, valued at approximately US$66.1 million, aims to advance Pharming's late-stage pipeline significantly. At the heart of this acquisition...

Continue Reading
Golden Sun Health Tech Launches Joint Venture in Tourism Sector

Updated Category News Views 113

Golden Sun Health Technology Group Limited Ventures into Cultural Tourism Golden Sun Health Technology Group Limited, previously known as Golden Sun Education Group Limited (NASDAQ: GSUN), has made a notable step forward by launching a joint venture aimed at tapping into the cultural tourism market. Through its wholly-owned subsidiary, Shanghai Golden Sun Gongyu Education...

Continue Reading
BlackRock Municipal Income Fund Announces Merger Dates and Changes

Updated Category News Views 520

BlackRock Municipal Income Fund Transition Announcement BlackRock Municipal Income Fund, Inc. (NYSE: MUI, referred to as the “Fund”) is set to undergo an exciting transition. The Fund will change from an exchange-listed closed-end fund to an unlisted continuously-offered closed-end fund, which will conduct quarterly repurchases of its shares. This new venture will be...

Continue Reading
Understand Your Rights: Join CrowdStrike Class Action Today

Updated Category News Views 152

Understanding the CrowdStrike Holdings Class Action Attention shareholders of CrowdStrike Holdings, Inc. (NASDAQ: CRWD): If you acquired shares during the specified class period, it’s important to understand your rights regarding an ongoing class action. Recent developments have raised concerns about the company's operations, particularly in relation to its flagship...

Continue Reading